OpenAI acquires Orchestra Bio

OpenAI has acquired Orchestra Bio, a platform designed to help biopharma teams manage the complex drug development process. The acquisition brings Orchestra's team and technology together with Rosalind, OpenAI's AI models and tools for life sciences research, including GPT-Rosalind that aids reasoning in biology and chemistry, and Rosalind Workbench that connects capabilities with scientific tools and data. Drug development is extremely complex, taking 10 to 15 years on average from target discovery to regulatory approval in the US, with teams often relying on disconnected systems. OpenAI aims to build AI agents that help teams connect scientific findings with the studies, decisions, and next steps needed to advance potential medicines. Orchestra Bio provides a platform where people and AI agents collaborate to advance drug programs, allowing scientists and program leaders to delegate monitoring and tracking of studies to agents, freeing time for decision-making. The platform helps teams identify which activities and timelines are affected by problems, gather relevant information, and compare response options. OpenAI emphasizes that realizing AI's potential in life sciences requires collaboration with organizations at the forefront of drug discovery, citing partnerships with Novo Nordisk to translate scale and scientific expertise into faster R&D and commercial execution, and with Moderna where AI helps translate complex data into experimental workflows. The vision is for AI to assist scientists across the full process of discovering and developing new medicines, from exploring ideas and designing experiments to interpreting results and coordinating work, with the goal of making more discoveries possible and helping new medicines reach patients sooner.

(Source：OpenAI)